ENTITY: NOVO NORDISK A/S

A Macro Intelligence Memo | June 2030 | CEO & Board Strategy Edition

FROM: The 2030 Report DATE: June 30, 2030 RE: Novo Nordisk - GLP-1 Market Leadership, Manufacturing Capacity Strategy, and Competitive Positioning in Weight-Loss Market (2025-2035) CLASSIFICATION: Confidential - Pharmaceutical Sector & Strategic Leadership Analysis AUDIENCE: Pharma CEOs, board directors, healthcare investors, pharmaceutical manufacturing specialists

SUMMARY: THE BEAR CASE vs. THE BULL CASE

BEAR CASE (Selective GLP-1 Expansion - Actual Path)

Novo Nordisk expands GLP-1 portfolio (semaglutide, retatrutide, oral formulations), achieves 18-20% revenue CAGR 2025-2030 (DKK 97B to DKK 224B), expands operating margin from 31% to 38%. GLP-1 weight-loss represents 26-29% of revenue by 2030. Manufacturing capacity managed carefully (€2-3B annual capex). Dividend growth DKK 4.50-5.50 per share. Stock appreciation targets 14-16% annually.

Financial Impact (Bear Case 2035): - Revenue: DKK 340-380B - Operating Margin: 39-41% - GLP-1 % Revenue: 35-40% - Stock CAGR 2030-2035: 14-16%

BULL CASE (Aggressive GLP-1 Dominance + Indications Expansion - 2025)

Had Novo committed €4-5B R&D to expand GLP-1 into NASH, cardiovascular, kidney disease indications and pursued premium pricing (€800-1,200 annually per patient), the company would have achieved 22-25% revenue CAGR and 41-43% operating margins by 2030. GLP-1 reaches 40-45% of revenue. Manufacturing capex accelerated (€4-5B annually). Dividend growth DKK 6.00-7.00 per share. Stock CAGR reaches 16-18%.

Financial Impact (Bull Case 2035): - Revenue: DKK 380-420B - Operating Margin: 42-44% - GLP-1 % Revenue: 45-50% - Stock CAGR 2030-2035: 16-18%

EXECUTIVE SUMMARY

Novo Nordisk experienced the most rapid commercial success of any major pharmaceutical company during 2025-2030. GLP-1 receptor agonist drugs (semaglutide, retatrutide) evolved from niche diabetes treatment to mass-market weight-loss category, driven by clinical efficacy, celebrity endorsements, insurance coverage expansion, and social media momentum. Revenue from GLP-1 products (weight-loss indication) exploded from approximately DKK 10 billion (2025) to DKK 55-60 billion annualized (2030), representing 26-29% of total company revenue.

Financial Position (June 2030): - Total revenue: DKK 224 billion (USD $30 billion), up 132% from 2025 - GLP-1 revenue: DKK 55-60 billion annualized (USD $7.4-8.0 billion) - Operating margin: 38% (up from 31% in 2025) - Global GLP-1 market share: 52% (largest player) - Stock appreciation since 2025: +285% - Market capitalization: USD $180 billion

Novo Nordisk faces critical strategic decisions across four dimensions: (1) manufacturing capacity expansion, (2) pricing strategy in face of payer pressure, (3) oral formulation development and market transition, (4) competitive positioning against better-capitalized rivals (Eli Lilly gaining market share, Amgen entering market). The company's leadership position is strong but under sustained attack from competitors with larger resources and in some cases superior product efficacy.

SECTION 1: THE GLP-1 MARKET EXPLOSION (2025-2030)

Market Origins and Transformation

GLP-1 receptor agonists were originally developed for Type 2 diabetes management. Novo Nordisk's semaglutide (branded Ozempic for diabetes, Wegovy for weight-loss) was FDA-approved for chronic weight management in 2021 but remained a niche indication through 2024.

The Transformation Phase (2026-2028):

1. Perceived Celebrity Endorsements: High-profile individuals publicly disclosed Ozempic/Wegovy use, normalizing weight-loss pharmacotherapy
2. Off-Label Prescribing: Physicians prescribed diabetes formulations off-label for weight-loss (cheaper due to higher dosages for diabetes, faster access)
3. Social Media Influence: TikTok, Instagram, influencer content about weight-loss drugs drove consumer demand particularly among Gen Z
4. Clinical Evidence Publication: Robust long-term efficacy data (15-22% body weight loss over 68 weeks) demonstrated clinical superiority vs. prior weight-loss drugs
5. Insurance Coverage Expansion: Payers began covering weight-loss indications (motivated by obesity prevalence and healthcare costs of obesity-related conditions)
6. Shortage-Driven Narrative: Supply constraints created perception of high demand, amplifying consumer interest

Market Size Trajectory (2024-2030)

Global GLP-1 Weight-Loss Market Evolution: - 2024: DKK 15 billion global market - 2025: DKK 22 billion (+47%) - 2026: DKK 38 billion (+73%) - 2027: DKK 62 billion (+63%) - 2028: DKK 110 billion (+77%) - 2029: DKK 158 billion (+44%) - 2030: DKK 190 billion estimated (+20%, growth moderation from peak rates)

The market experienced 12-13x expansion over 6 years, representing fastest adoption trajectory of any pharmaceutical drug class in modern history.

Patient Population and Market Penetration

Current Penetration (June 2030): - Global obesity (BMI >30): 1.2 billion people - GLP-1 treatment candidates: 300-400 million (motivated to lose weight, able to pay or insured) - Actual GLP-1 users (June 2030): ~40 million people (10-15% of candidates) - Annualized new user additions: ~8-10 million people

Future Penetration Estimates: - 2035 target: 80-100 million users (realistic market ceiling) - Penetration rate: 20-25% of candidates by 2035

Market still in early adoption phase despite explosive growth. Future growth potential remains substantial but growth rates moderating from 2026-2028 peak (70%+ CAGR).

SECTION 2: NOVO NORDISK'S COMPETITIVE POSITIONING (JUNE 2030)

Market Share and Competitive Dynamics

Novo Nordisk Market Position: - Global market share: 52% (DKK 99 billion of DKK 190 billion market) - Revenue breakdown: DKK 55-60B from weight-loss; DKK 40B from diabetes - Growth rate: +40-45% YoY (still rapid despite moderation)

Competitive Landscape: - Eli Lilly (tirzepatide, brand Mounjaro): 35% market share, rapidly gaining - Efficacy advantage: 20-22% weight loss vs. Novo's 15-18% - Aggressive capacity expansion and pricing strategy - Better-capitalized for market development - Amgen (MariTide): <5% market share, entering 2030-2031 - Monthly injection (vs. weekly for existing products) - Different pharmacodynamic profile - Limited market presence but potential for rapid growth - Others (Roche, Pfizer, others): ~10% combined market share

Manufacturing Constraint as Strategic Advantage

Paradoxically, Novo Nordisk's ability to supply market is constrained:

Supply Constraint Reality: - Current manufacturing capacity: ~15-18 billion dose units annually - Estimated 2030 demand: 20-24 billion units (40-50% shortfall) - Allocation system: Rationing to priority markets (US, Western Europe) - Backorders: 6-12 months in many secondary markets - Shortage narrative: Persistent shortage positioning supports pricing power

Strategic Implication: Supply scarcity maintains pricing power and prevents margin compression that would accompany oversupply. From a financial perspective, capacity constraint is advantage (supports margins). From market perspective, constraint limits growth opportunity and competitor positioning.

SECTION 3: CRITICAL STRATEGIC DECISIONS (2030-2035)

Decision 1: Manufacturing Capacity Expansion Strategy

Novo Nordisk must choose aggressive vs. moderate capacity expansion approach.

Option A: Aggressive Expansion (100+ billion unit capacity by 2032) - Capital requirements: DKK 15-20 billion capex - Timeline: 3-5 years to full capacity - Implications: Eliminates supply constraints, maintains market share leadership, supports 40%+ CAGR through 2035 - Risks: Overinvestment if demand plateaus; margin compression if oversupply emerges - Financial impact: Supporting faster growth but at execution and capex risk

Option B: Capacity Matching Demand (50-60 billion unit capacity) - Capital requirements: DKK 8-10 billion capex - Timeline: 2-3 years - Implications: Moderate growth acceleration, maintains supply scarcity advantage - Risks: Underinvestment; potential market share loss to competitors with more aggressive expansion - Financial impact: Lower capital risk; preserves supply advantage but may sacrifice market position

Option C: Selective Expansion + CMO Partnerships - Leverage Contract Manufacturing Organizations (CMOs) for incremental capacity - Capital requirements: DKK 3-5 billion - Implications: Lower capital intensity, flexibility - Risks: Quality control/supplier dependency; third-party reputation risk - Financial impact: Lower capex but potential margin pressure from CMO pricing

Recommendation: Option A (Aggressive Expansion)

Rationale: (1) Manufacturing is core competitive moat; first-mover capacity advantage provides lasting competitive benefit; (2) Market growth trajectory (40M users 2030 to 100M+ users 2035) justifies aggressive investment; (3) Competitors (Eli Lilly, Amgen) expanding capacity aggressively; underinvestment risks permanent market share loss; (4) DKK 15-20B capex is manageable given free cash flow generation (DKK 40-50B+ annually).

Decision 2: Pricing Strategy (Price Maintenance vs. Compression)

Novo Nordisk faces intense payer pressure for 30-50% price reductions while simultaneously having pricing power from supply scarcity.

Option A: Price Maintenance (Current Price Levels) - Revenue benefit: Short-term profitability maximization - Risk profile: High—regulatory/political backlash; potential market share loss - Outcome: Likely unsustainable amid payer/political pressure; eventually forced to reduce prices on worse terms

Option B: Moderate Price Compression (10-15% over 5 years) - Accept gradual pricing pressure while maintaining market share - Pass some savings to payers/patients/insurers - Volume growth (100M patients at lower prices) generates more absolute profit than 40M patients at high prices - Revenue impact: Trading short-term price for long-term volume - Recommendation: Optimal strategy

Rationale: (1) Volume growth more important than price maintenance; (2) Regulatory pressure inevitable; better to control narrative; (3) Market share leadership valuable; worth trading 10-15% price for #1 position; (4) Long-term competitive positioning (licensing, partnerships, M&A) depends on market leadership.

Decision 3: Oral Formulation Development

Injectable formulations dominate 2025-2030. Oral formulations in development (Novo Nordisk and competitors) represent next-generation product with significant advantages: - Patient preference (oral vs. injection) - Cheaper to manufacture - Potential for market expansion (patients avoiding injections)

Development Timeline: Oral semaglutide likely 2033-2034 launch

Investment Decision: - R&D budget: DKK 5-8 billion over 5-7 years - Recommendation: Aggressive oral investment - Rationale: Patent expiration (semaglutide 2035-2038) creates urgency; oral transition inevitable; first-mover in oral market extension provides competitive advantage

Decision 4: M&A and Ecosystem Strategy

Opportunities to acquire complementary obesity treatment companies/technologies: - Medical devices (endoscopic sleeves, gastric balloons) - Digital health (apps, coaching, counseling platforms) - Combination therapeutics (obesity + other conditions)

Recommended M&A Allocation: DKK 10-15 billion over 2030-2032

Rationale: Build integrated obesity treatment ecosystem (pharmaceuticals + devices + digital); differentiate from pure-play pharma competitors; create moat beyond drug efficacy.

SECTION 4: FINANCIAL PROJECTIONS AND SCENARIOS

Revenue Projections (FY2030-FY2035)

Base Case Scenario: - FY2030: DKK 224 billion (actual) - FY2031E: DKK 270 billion (+20% YoY) - FY2032E: DKK 310 billion (+15% YoY) - FY2033E: DKK 340 billion (+10% YoY) - FY2034E: DKK 360 billion (+6% YoY) - FY2035E: DKK 375 billion (+4% YoY)

GLP-1 revenue growth (DKK 55B to DKK 110-130B by 2035) reflects patient volume doubling and partial oral transition.

Operating Margin Trajectory

Margin Evolution (Base Case): - FY2030: 38% (current, supply-constrained, high prices) - FY2032: 36% (modest compression from price reductions, capacity ramp) - FY2034: 34% (normalization; competitive pressure; oral transition costs) - FY2035: 32% (supply normalized; intense competition; margin normalization)

Margins decline gradually as market matures but remain well above historical average (25-28%), supporting continued strong profitability.

Capital Requirements and Cash Flow

Major Capex Needs (2030-2035): - Manufacturing expansion: DKK 15-20 billion - R&D (oral formulations, combinations): DKK 8-12 billion - M&A (obesity ecosystem): DKK 10-15 billion - Total capex/M&A: DKK 33-47 billion

Anticipated Cash Generation: - Free cash flow: DKK 40-50 billion annually (2031-2035) - Capacity: Company generates sufficient cash to fund all investments without external financing

SECTION 5: RISK ASSESSMENT AND COMPETITIVE THREATS

Competitive Risks

Eli Lilly Threat (Primary Competitive Risk): - Superior efficacy (tirzepatide 20-22% vs. semaglutide 15-18% weight loss) - Aggressive capacity expansion - Larger pharmaceutical company resources (AbbVie ownership) - Potential to achieve market leadership by 2034-2035 - Mitigation: Aggressive R&D (new formulations, combinations), maintain capacity advantage, brand loyalty

Amgen Entry (Secondary Risk): - MariTide (monthly injection) entering 2030-2031 - Differentiated dosing schedule (monthly vs. weekly) - Could capture patient preference segment - Limited immediate threat but potential for growth - Mitigation: Feature development (longer-acting formulations), patient education, bundling with devices

Regulatory/Safety Risks: - Long-term safety data limited (drugs in use <10 years) - If safety issues emerge (thyroid cancer, pancreatitis recurrence), market could contract - Mitigation: Rigorous post-market surveillance, transparent safety communication

Market Risks

Price Pressure: - Healthcare systems demanding 30-50% reductions - Public/political pressure for affordability - Mitigation: Accept moderate (10-15%) price compression; emphasize volume expansion offsetting price decline

SECTION 5B: COMBINATION THERAPY DEVELOPMENT AND COMPETITIVE DIFFERENTIATION

By 2030, early evidence suggested that GLP-1 monotherapy, while highly effective, reaches efficacy plateau around 15-22% body weight loss. Additional weight loss or metabolic benefits require either: 1. Higher doses (increasing side effects and manufacturing burden) 2. Combination with other pharmacotherapies targeting complementary pathways

Novo Nordisk is pursuing combination therapy development as critical differentiator vs. competitors with single-mechanism products.

Combination Therapy Pipeline (Phase 2-3 Development 2030):

Combination 1: GLP-1 + GIP Dual Receptor Agonist - Retatrutide (Novo's dual agonist) showed superior efficacy (22% weight loss at higher doses) vs. GLP-1 monotherapy - Emerging data suggests triple mechanisms (GLP-1 + GIP + GCG) may offer 25-30% weight loss with acceptable tolerability - Novo advancing tirzepatide competitor (Novo's oral GLP-1/GIP combination) - Expected launch timeline: 2033-2034 - Strategic importance: Counters Eli Lilly's efficacy advantage

Combination 2: GLP-1 + SGLT-2 Inhibitor - GLP-1 drives weight loss; SGLT-2i provides cardiovascular and renal protection - Metabolically complementary: Addresses obesity + metabolic disease in one regimen - Partnership potential: Novo has been in discussions with cardiovascular pharma (J&J) for combination development - Target patient: Obese patients with diabetes/hypertension (60%+ of obesity market) - Expected launch: 2034-2035

Combination 3: GLP-1 + Amylin Analog - Amylin agonism targets satiety, potentially offering additional weight loss benefit - Earlier-stage (Phase 2) but strategically interesting - Development cost: DKK 2-3B - Timeline: 2035-2036 potential launch

Financial Impact of Combinations:

By 2035, combination therapies could represent 30-40% of Novo's obesity revenue:

Combination therapies offer higher margins (fewer competitive alternatives, patent protection) and address larger addressable market (obese patients with comorbidities).

R&D Investment Required: DKK 8-12B over 5 years to advance combination pipeline to market. This is reflected in earlier Sections 3-4 capex guidance.

Competitive Advantage: Eli Lilly's tirzepatide is superior monotherapy but has limited combination development pipeline. Novo's combinations could restore competitive advantage despite tirzepatide efficacy lead.

SECTION 5C: DIGITAL HEALTH INTEGRATION AND PATIENT ECOSYSTEM

Obesity is not a pharmaceutical-only problem. Patient success requires: - Diet/nutrition coaching - Exercise programming - Behavioral change support - Adherence monitoring - Long-term outcome tracking

Novo Nordisk is building digital health ecosystem to integrate with pharmaceutical offerings:

Digital Health Initiatives (2028-2030):

1. Novo Obesity App (Launched 2028) - Patient community platform for users of GLP-1 drugs - Features: Nutrition tracking, exercise logging, community forums, progress tracking, educational content - Adoption: 4-5M users by June 2030 (10-12% of active GLP-1 patients) - Engagement: 40% monthly active users (strong for health apps) - Monetization: Direct-to-patient subscription model (DKK 50-100/month), B2B with healthcare systems

2. Healthcare Provider Integration Platform - Novo's SaaS platform connecting prescribers with patient monitoring - Features: Real-time patient adherence tracking, side effect monitoring, dose optimization, outcome reporting - Uptake: 2,000+ healthcare providers (clinics, hospitals) using platform by June 2030 - Strategic value: Data collection on real-world outcomes (competitive advantage for future trials)

3. Obesity Management Ecosystem Partnerships - Partnership with WW (formerly Weight Watchers) for digital integration (2029) - Integrating Novo app with WW nutrition database/community - Revenue share arrangement (estimated DKK 100-150M annually by 2030)

4. Genetic Testing and Personalized Therapy - Emerging research showing genetic variants predict GLP-1 response - Novo investing in proprietary genetic testing (pharmacogenomics) to personalize therapy selection - Potential launch of "Novo Obesity Profiling" test by 2032-2033 - Strategic value: Differentiation; justifies premium pricing for genetically-optimized therapy selection

Financial Impact:

Digital health currently contributes <DKK 200M to revenue (testing, SaaS, partnerships). Projected growth:

While digital health is still nascent, strategic importance is significant: - Creates switching costs (patients embedded in Novo ecosystem) - Generates real-world data (valuable for competitive differentiation) - Enables premium pricing justification (comprehensive solution, not just drug) - Supports market share defense vs. pure-play competitors

SECTION 5D: GEOGRAPHIC EXPANSION AND MARKET PENETRATION STRATEGY

Current Geographic Revenue Mix (2030):

North America dominates (49% of revenue) but Asia-Pacific growing fastest.

Market-by-Market Expansion Opportunity:

1. China Obesity Market (Priority Expansion)

China obesity market is massive (>300M obese individuals) but underpenetrated (GLP-1 adoption <1% vs. 10-15% in North America).

Barriers to expansion: - Limited insurance coverage for weight-loss drugs - Regulatory approval delays (NMPA approval of semaglutide for weight-loss obtained only in 2028) - Distribution/manufacturing in-country requirements - Price sensitivity (Chinese patients expect lower pricing than developed markets)

Novo's China Strategy: - Established manufacturing facility in Shanghai (2029) targeting local production - Partnership with Chinese distributor (China Pharma Holdings) for market access - Regulatory strategy for rapid approval of oral formulation in China - Pricing strategy: 40-50% discount vs. US/Europe (market penetration priority)

Financial Projection: - China obesity revenue (2030): DKK 3-4B - China obesity revenue (2035): DKK 15-20B - 5-year CAGR: 40-45% (fastest growth region)

China expansion could add DKK 15-20B to 2035 revenue vs. baseline projections.

2. India and Southeast Asia

India has massive obesity population (>150M obese individuals) but minimal GLP-1 penetration (regulatory approval delays, price sensitivity, weak insurance infrastructure).

Novo strategy: - License manufacturing to local partners (lower capex, faster market access) - Target medical tourism/cash-pay patients initially (build brand) - Partner with private health networks for distribution - Develop India-specific pricing (40-60% discount vs. developed markets)

Projected revenue impact: DKK 2-3B by 2035 (20-25% CAGR).

3. Latin America

Brazil, Mexico, Argentina have significant obesity prevalence and growing wealth. Market development slower than Asia but still attractive.

Projected revenue impact: DKK 1.5-2B by 2035.

Geographic Revenue Mix Projection (2035 vs. 2030):

Asia-Pacific revenue could triple, driven by China expansion. This partially offsets mature market growth constraints.

SECTION 5E: INTELLECTUAL PROPERTY AND PATENT STRATEGY

Patent protection is critical competitive moat for GLP-1 portfolio.

Patent Timeline (Critical Dates):

Patent Defense Strategy:

1. Continuation Patents: Novo pursuing continuation applications covering combination formulations, specific dosing regimens, patient populations—extending effective patent life beyond 2035
2. Pediatric Extension: FDA/EMA pediatric extension adds 6 months protection (achieved for semaglutide in 2026)
3. Data Exclusivity: Regulatory protections (10 years for new chemical entities, potentially longer for orphan indications) provide additional protection vs. generic competition
4. Trade Secrets: Formulation know-how, manufacturing processes, and combinations protected as trade secrets (indefinite protection if maintained)

Strategic Implication:

Strong patent portfolio provides pricing power and market protection through 2040-2045 for key products. Patent expiration 2035-2042 creates strategic pressure: oral formulations and combinations must launch before 2035-2038 to establish market position and patient loyalty before generic erosion.

SECTION 6: REVISED FINANCIAL PROJECTIONS AND STRATEGIC SCENARIOS

Scenario 1: Base Case (55% probability)

Assumptions: Moderate capacity investment, combination therapy launches 2033-2034, Asia expansion tracking projections.

Scenario 2: Bull Case (20% probability - Asia exceeds expectations, combination therapies early wins)

Bull case driven by: China market penetration faster than expected, combination therapies achieve superior efficacy enabling premium pricing, digital health monetization exceeds projections.

Scenario 3: Bear Case (25% probability - Competitive pressure, regulatory setback)

Bear case driven by: Eli Lilly gains market share with superior tirzepatide, pricing pressure intensifies, Asia expansion slower than planned, safety concerns limit market growth.

SECTION 7: REVISED BOARD DECISIONS REQUIRED (H2 2030)

1. Approve DKK 15-20 billion capex for manufacturing expansion (2030-2032)
2. Approve DKK 5-8 billion R&D budget for oral formulation development
3. Authorize selective M&A (DKK 10-15 billion) for obesity ecosystem
4. Accept pricing guidance allowing 10-15% price compression over 5 years
5. Confirm dividend policy (maintain current, modest growth)

CONCLUSION

Novo Nordisk has captured market leadership in the fastest-growing drug market in pharmaceutical history. Current position is strong but under sustained attack from competitors. Strategic imperative is: (1) invest aggressively in manufacturing (capacity is moat), (2) accept moderate pricing pressure, (3) develop next-generation products (oral formulations), (4) build integrated ecosystem.

Execution success through 2035 is likely but not certain. Competition intensifying, markets maturing, regulatory pressure mounting. Company's strategic choices (2030-2032) will determine whether Novo maintains leadership or becomes secondary player in increasingly competitive market.

The 2030 Report | Macro Intelligence Assessment | June 2030

REFERENCES & DATA SOURCES

1. Bloomberg (Q2 2030): "Novo Nordisk Q2 2030 Earnings: Obesity Drug Demand and Manufacturing"
2. McKinsey & Company (2030): "AI in Healthcare: Patient Outcome Optimization"
3. Reuters (2029): "Biopharmaceutical Manufacturing and Supply Chain Optimization"
4. Morgan Stanley Healthcare Equity Research (June 2030): "Pharma Valuations and Growth Drivers"
5. Gartner (2029): "Healthcare IT and Precision Medicine"
6. Goldman Sachs (2030): "Biopharmaceutical Sector Growth and Technology"
7. S&P Global (2030): "Pharmaceutical Company Financial Performance"
8. Deloitte (2030): "Life Sciences Digital Transformation"
9. Boston Consulting Group (2030): "Biopharmaceutical Innovation Strategy"
10. EvaluatePharm (2030): "Diabetes and Obesity Therapeutics Market"
11. World Health Organization (2030): "Global Obesity and Diabetes Epidemic"